Inflectra
E242408
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Inflectra canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T2190626 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Inflectra Context triple: [Remicade, hasBiosimilar, Inflectra]
-
A.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
B.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
C.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
D.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
E.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Inflectra Target entity description: Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
A.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
B.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
C.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
D.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
E.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
- F. None of above. chosen
Statements (40)
| Predicate | Object |
|---|---|
| instanceOf |
biologic drug
ⓘ
biosimilar medicine ⓘ monoclonal antibody ⓘ tumor necrosis factor inhibitor ⓘ |
| belongsToClass |
chimeric monoclonal antibodies
ⓘ
immunosuppressive agents ⓘ |
| contraindicatedIn |
patients with moderate or severe heart failure
ⓘ
patients with severe infections ⓘ |
| hasActiveSubstance | infliximab-dyyb ⓘ |
| hasATCCode | L04AB02 ⓘ |
| hasBlackBoxWarning |
malignancy risk
ⓘ
serious infections ⓘ |
| hasDosageForm | solution for infusion ⓘ |
| hasGenericName | infliximab-dyyb ⓘ |
| hasIndication |
Crohn’s disease
ⓘ
ankylosing spondylitis ⓘ plaque psoriasis ⓘ psoriatic arthritis ⓘ rheumatoid arthritis ⓘ ulcerative colitis ⓘ |
| hasPregnancyCategory | risk–benefit must be individually assessed ⓘ |
| hasStorageCondition | refrigerated storage ⓘ |
| isAdministeredWith | methotrexate in rheumatoid arthritis ⓘ |
| isBiosimilarTo |
infliximab
ⓘ
linked to:
Remicade
|
| isIntendedFor |
adult patients
ⓘ
pediatric patients for certain indications ⓘ |
| isNotInterchangeableWith | reference infliximab without prescriber authorization in some jurisdictions ⓘ |
| mayCause |
increased risk of serious infections
ⓘ
infusion-related reactions ⓘ reactivation of latent tuberculosis ⓘ |
| mechanismOfAction | binds to TNF-alpha and neutralizes its activity ⓘ |
| regulatoryDesignation | biosimilar ⓘ |
| requiresMonitoring |
hepatitis B reactivation
ⓘ
tuberculosis prior to treatment ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targets | tumor necrosis factor alpha ⓘ |
| usedFor |
autoimmune inflammatory diseases
ⓘ
moderate to severe Crohn’s disease ⓘ moderate to severe rheumatoid arthritis ⓘ moderate to severe ulcerative colitis ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Inflectra Description of subject: Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.